February 10, 2015

The Generic Pharmaceutical Association on Monday announced the election of its 2015 executive committee and board of directors.

January 12, 2015

Perrigo and Ferrara Candy Co. announced Monday that Perrigo's Nutritionals division has signed a supply agreement with Ferrara to manufacture store brand gummy vitamins and dietary supplements.

January 12, 2015

Perrigo on Monday announced that it has launched clobetasol propionate spray, 0.05%, the generic equivalent to Clobex spray, 0.05%. 

January 12, 2015

Perrigo Co. on Monday announced the launch of testosterone gel 1%, the therapeutic equivalent to Androgel 1% from AbbVie. 

December 2, 2014

Perrigo on Tuesday announced that it has received final approval from the Food and Drug Administration on its abbreviated new drug application for diclofenac sodium topical solution 1.5% w/w.

November 24, 2014

Perrigo on Monday announced that it has agreed to market the authorized generic version of Astellas U.S.' Protopic ointment 0.1% and 0.03%. 

November 19, 2014

7‑Eleven, which has long offered single-dose blister packs of the most popular, national brand over-the-counter medications, on Tuesday entered the private-label drug business.

November 7, 2014

It's one month into the cough-cold season and illness rates are up 3%, noted Matthew Mannelly, Prestige Brands president and CEO.

November 7, 2014

Perrigo may one day expand into the branded side of the U.S. OTC business, Joseph Papa, Perrigo president, chairman and CEO, told analysts Thursday morning.

November 6, 2014

Perrigo and Omega Pharma announced that they have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for $4.5 billion.

November 6, 2014

Perrigo on Thursday announced that it has reinitiated shipments of Guaifenesin 600mg Extended-Release tablets to its retail and wholesale customers in the United States.

July 30, 2014

Perrigo on Wednesday announced that it has filed an abbreviated new drug application with the Food and Drug Administration for desoximetasone topical spray 0.25%. The company also has notified Taro Pharmaceuticals U.S.A., the owner of the reference listed drug, of the filing.

June 20, 2014

Teva has reached a settlement with Perrigo Pharmaceutical and Catalent Pharma Solutions with respect to four patents for Teva’s ProAir HFA (albuterol sulfate) Inhalation aerosol product.

May 12, 2014

Perrigo on Monday announced that it received approval from the Food and Drug Administration for azelastine hydrochloride nasal spray (0.15%), a generic version of Astepro. The drug is indicated for people ages 12 years and older and is used to treat nasal symptoms brought on by seasonal allergies or environmental irritants.

April 21, 2014

By adding complementary specialty medication offerings to their generic drug businesses, manufacturers can add instant value and counteract the margin compression that is currently occurring as a result of high generic drug utilization.

March 26, 2014

Perrigo announced that its Nutritionals segment is partnering with KanPak to manufacture store brand adult nutritional drinks comparable to Ensure products.

March 18, 2014

The Consumer Healthcare Products Association on Tuesday announced the members of the CHPA Educational Foundation Board during the association’s Annual Executive Conference held here.

March 13, 2014

Perrigo announced the launch of methazolamide tablets, the generic version of Neptazane tablets. The product is a component of the rights the company received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals and its affiliates last year.

March 10, 2014

Two Rx-to-OTC switches in the past year may serve as a harbinger of what the Food and Drug Administration will consider “switch” worthy.

February 28, 2014

Perrigo on Friday announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global for $51 million in cash.

January 24, 2014

Perrigo announced that it received final approval from the Food and Drug Administration for repaglinide tablets — a generic version of Prandin tablets.

January 15, 2014

Perrigo on Tuesday announced that it has received final approval for its abbreviated new drug application for fluocinonide cream 0.1%, the generic equivalent to prescription-only Vanos Cream 0.1%.

December 18, 2013

Perrigo has finalized its acquisition of Elan Corp., Perrigo said Wednesday.